Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates
Bolt Biotherapeutics, Inc. BOLT
$6.30
▼ -2.02%
($-0.13)
🎈 Low Float
📅 Earnings This Week
Open
$6.16
Prev Close
$6.43
Day Range
$6.16 – $6.66
52W Range
$3.10 – $7.78
Market Cap
$12.39M
Beta
0.96
EPS (TTM)
$-16.44
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-02-05 |
| Shares Out. | 2,590,000 |
| Website | boltbio.com ↗ |
| Phone | 13025310855 |
| Employees | 23 |
| Revenue | $5,000 |
| Gross Profit | $5,000 |
| Net Income | -$7.7M |
| Free Cash Flow | -$31.5M |
| Total Assets | $40.3M |
| Total Liabilities | $27.7M |
| Equity | $12.6M |
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Bolt Biotherapeutics, Inc. is a publicly traded company under the ticker symbol BOLT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-11-01)